, _	Application No.	Applicant(s)
Notice of Allowability	09/614,221 Examiner	KARUNANANDAA ET AL.
	Russell Kallis	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. \[\begin{align*} \text{This communication is responsive to \(\frac{9/17/2003}{2} \). 2. \[\begin{align*} \text{The allowed claim(s) is/are \(\frac{28-29 \) (renumbered 1-2)}{2} \). 3. \[\begin{align*} \text{The drawings filed on are accepted by the Examiner.} 4. \[\begin{align*} \text{Acknowledgment is made of a claim for foreign priority under 35 U.S.C. \(\frac{5}{2} \) 119(a)-(d) or (f). a) \[\begin{align*} \text{All claims of the priority documents have been received.} 2. \[\begin{align*} \text{Certified copies of the priority documents have been received in Application No 3. \[\begin{align*} \text{Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). \[\begin{align*} \text{Certified copies not received: 5. \[\text{Acknowledgment is made of a claim for domestic priority under 35 U.S.C. \(\frac{5}{2} \) 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. (a) \[\begin{align*} \text{The MAILING DATE on the included in the foreign language provisional application has been received. \end{align*}		
 Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF 		
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d). 9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
 1 □ Notice of References Cited (PTO-892) 2 □ Notice of Draftperson's Patent Drawing Review (PTO-948) 3 □ Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No. 20030917 4 □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	6 ⊠ Interview Su 7⊠ Examiner's A	ormal Patent Application (PTO-152) mmary (PTO-413), Paper No. 2063 II/D Amendment/Comment Statement of Reasons for Allowance

Art Unit: 1638

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In the Title:

The Title was amended as follows:

-- $\underline{\Lambda}$ nucleic acid molecule[s] and [other molecules] <u>encoded protein</u> associated with sterol synthesis and metabolism.--

In the Abstract:

The Abstract was amended as follows:

--This invention relates to the field of biotechnology, particularly as it pertains [to the production of sterols in a variety of host systems particularly plants. More specifically, the invention relates] to a nucleic acid molecule[s] encoding a protein[s] [and fragments of proteins] associated with sterol and phytosterol synthesis and metabolism [as well as the encoded proteins and fragments of proteins and antibodies capable of binding to them]. The invention also relates to methods of detection using the nucleic acid molecule[s], [fragments of the nucleic acid molecules, proteins, and fragments of proteins] or the encoded protein as a probe or in a microarray. [The invention also relates to cells, organisms, plants, or seeds, or progeny of any, that have been manipulated to contain increased levels or overexpress at least one sterol or phytosterol compound.]--

Application/Control Number: 09/614,221 Page 3

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Russell Kallis whose telephone number is (703) 305-5417. The examiner can normally be reached on M-F 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0198.

Russell Kallis November 11, 2003

DAVID T. FOX
PRIMARY EXAMINER

GROUP 180 1603 8